Bone marrow microenvironment: The guardian of leukemia stem cells

被引:33
作者
Houshmand, Mohammad [1 ]
Blanco, Teresa Mortera [2 ]
Circosta, Paola [1 ]
Yazdi, Narjes [3 ]
Kazemi, Alireza [4 ]
Saglio, Giuseppe [1 ]
Zarif, Mahin Nikougoftar [2 ,5 ]
机构
[1] Univ Turin, Dept Clin & Biol Sci, I-10126 Turin, Italy
[2] Karolinska Inst, Ctr Hematol & Regenerat Med, Karolinska Univ Hosp Huddinge, Dept Med, S-14183 Stockholm, Sweden
[3] Islamic Azad Univ, Dept Mol Genet, Tehran Med Branch, Tehran 1916893813, Iran
[4] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Hematol & Blood Banking, Tehran 1985717443, Iran
[5] High Inst Res & Educ Intransfus Med, Blood Transfus Res Ctr, Tehran 146651157, Iran
来源
WORLD JOURNAL OF STEM CELLS | 2019年 / 11卷 / 08期
关键词
Bone marrow microenvironment; Bone marrow niche; Leukemic stem cell; Chronic myeloid leukemia; Acute myeloid leukemia; Target therapy; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; BCR-ABL; ENDOTHELIAL-CELLS; PROGENITOR CELLS; TYROSINE KINASE; BETA-CATENIN; CML STEM; PROGNOSTIC-FACTOR;
D O I
10.4252/wjsc.v11.i8.476
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Bone marrow microenvironment (BMM) is the main sanctuary of leukemic stem cells (LSCs) and protects these cells against conventional therapies. However, it may open up an opportunity to target LSCs by breaking the close connection between LSCs and the BMM. The elimination of LSCs is of high importance, since they follow cancer stem cell theory as a part of this population. Based on cancer stem cell theory, a cell with stem cell-like features stands at the apex of the hierarchy and produces a heterogeneous population and governs the disease. Secretion of cytokines, chemokines, and extracellular vesicles, whether through autocrine or paracrine mechanisms by activation of downstream signaling pathways in LSCs, favors their persistence and makes the BMM less hospitable for normal stem cells. While all details about the interactions of the BMM and LSCs remain to be elucidated, some clinical trials have been designed to limit these reciprocal interactions to cure leukemia more effectively. In this review, we focus on chronic myeloid leukemia and acute myeloid leukemia LSCs and their milieu in the bone marrow, how to segregate them from the normal compartment, and finally the possible ways to eliminate these cells.
引用
收藏
页码:476 / 490
页数:15
相关论文
共 103 条
  • [1] Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Agarwal, Anupriya
    Fleischman, Angela G.
    Petersen, Curtis L.
    MacKenzie, Ryan
    Luty, Samuel
    Loriaux, Marc
    Druker, Brian J.
    Woltjer, Randall L.
    Deininger, Michael W.
    [J]. BLOOD, 2012, 120 (13) : 2658 - 2668
  • [2] IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
    Agerstam, Helena
    Hansen, Nils
    von Palffy, Sofia
    Sanden, Carl
    Reckzeh, Kristian
    Karlsson, Christine
    Lilljebjorn, Henrik
    Landberg, Niklas
    Askmyr, Maria
    Hogberg, Carl
    Rissler, Marianne
    Porkka, Kimmo
    Wadenvik, Hans
    Mustjoki, Satu
    Richter, Johan
    Jaras, Marcus
    Fioretos, Thoas
    [J]. BLOOD, 2016, 128 (23) : 2683 - 2693
  • [3] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
    Aguayo, A
    Kantarjian, H
    Manshouri, T
    Gidel, C
    Estey, E
    Thomas, D
    Koller, C
    Estrov, Z
    O'Brien, S
    Keating, M
    Freireich, E
    Albitar, M
    [J]. BLOOD, 2000, 96 (06) : 2240 - 2245
  • [4] Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche
    Arai, F
    Hirao, A
    Ohmura, M
    Sato, H
    Matsuoka, S
    Takubo, K
    Ito, K
    Koh, GY
    Suda, T
    [J]. CELL, 2004, 118 (02) : 149 - 161
  • [5] Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
    Barreyro, Laura
    Will, Britta
    Bartholdy, Boris
    Zhou, Li
    Todorova, Tihomira I.
    Stanley, Robert F.
    Ben-Neriah, Susana
    Montagna, Cristina
    Parekh, Samir
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Paietta, Elisabeth
    Ketterling, Rhett P.
    Cripe, Larry
    Fernandez, Hugo F.
    Greenberg, Peter L.
    Tallman, Martin S.
    Steidl, Christian
    Mitsiades, Constantine S.
    Verma, Amit
    Steidl, Ulrich
    [J]. BLOOD, 2012, 120 (06) : 1290 - 1298
  • [6] Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
    Beider, Katia
    Darash-Yahana, Merav
    Blaier, Orly
    Koren-Michowitz, Maya
    Abraham, Michal
    Wald, Hanna
    Wald, Ori
    Galun, Eithan
    Eizenberg, Orly
    Peled, Amnon
    Nagler, Arnon
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) : 1155 - 1169
  • [7] Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
    Bellamy, WT
    Richter, L
    Sirjani, D
    Roxas, C
    Glinsmann-Gibson, B
    Frutiger, Y
    Grogan, TM
    List, AF
    [J]. BLOOD, 2001, 97 (05) : 1427 - 1434
  • [8] Benito Juliana, 2013, Int J Hematol Oncol, V2, P279
  • [9] Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
    Bhatia, R
    McCarthy, JB
    Verfaillie, CM
    [J]. BLOOD, 1996, 87 (09) : 3883 - 3891
  • [10] Bone and the hematopoietic niche: a tale of two stem cells
    Bianco, Paolo
    [J]. BLOOD, 2011, 117 (20) : 5281 - 5288